Accéder au contenu
Merck

Safety of ofloxacin otic and other ototopical treatments in animal models and in humans.

The Pediatric infectious disease journal (2001-02-15)
G A Gates
RÉSUMÉ

To assess the safety of topical agents in the middle ear, animal studies were reviewed. Compared with aminoglycoside-containing preparations, which caused significant loss of hair cells in the basal turn of the cochlea, ofloxacin caused no loss of hair cells, even at concentrations higher than used clinically. Moreover auditory brainstem testing revealed no change in auditory thresholds in the ofloxacin-treated animals, whereas neomycin-treated animals showed substantial threshold shifts. In human studies, use of topical ofloxacin 0.3% was not associated with any change in hearing. Topical ofloxacin has no demonstrable adverse effects on middle ear or cochlear function.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ofloxacin, fluoroquinolone antibiotic
USP
Ofloxacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Ofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ofloxacin, VETRANAL®, analytical standard
Ofloxacin, European Pharmacopoeia (EP) Reference Standard